BEHAVIORAL ALTERATIONS IN OPEN FIELD TEST IN AN EXPERIMENTAL MODEL OF PROSTATITIS

  • Aleksa Zubelić Laboratorija za neurofiziologiju, Institut za medicinsku fiziologiju ‘‘Rihard Burjan‘‘, Medicinski fakultet, Univerzitet u Beogradu
  • Božo Knežević Laboratorija za neurofiziologiju, Institut za medicinsku fiziologiju ‘‘Rihard Burjan‘‘, Medicinski fakultet, Univerzitet u Beogradu
  • Željko Grubač Laboratorija za neurofiziologiju, Institut za medicinsku fiziologiju ‘‘Rihard Burjan‘‘, Medicinski fakultet, Univerzitet u Beogradu
  • Nikola Sutulovic
  • Olivera Stanojlović
  • Dragan Hrncic
DOI: https://doi.org/10.5937/mp70-22242

Abstract


Introduction: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is one of the most common diseases of genitourinary system in male population. It is frequently accompanied by psychosocial disorders which include anxiety. Despite numerous clinical studies, the mechanisms of this link are still unclear, partly due to the lack of studies on experimental animal models.
Aim: The aim of this study was to examine locomotion activity and anxiety in rats, with experimentally induced CP/CPPS, using the open field test.
Material and methods: Wistar male rats were randomly distributed into control and experimental group. In experimental group, CP/CPPS was induced by single intraprostatic injection of 3% λ-carrageenan. Development of pelvic pain syndrome was assessed by evaluating mechanical pain thresholds by electronic Von Frey aesthesiometer (eVF). The rats were individually tested in the open field, seventh day following the intraprostatic injection.
Results: In animals from the experimental group, distance and time of ambulatory movement in the open field test were significantly decreased, number of rearing reduced, time spent in the center of the open field significantly decreased, while index of thigmotaxis was significantly increased compared to the control animals.
Conclusion: Results of this study indicate anxiogenic effect of CP/CPPS in rats.

Keywords: chronic prostatitis, chronic pelvic pain syndrome, open field test, anxiety, rats

References

Passavanti, M.B, Pota V, Sansone P, Aurilio C, De Nardis L, Pace M.C. Chronic Pelvic Pain: Assessment, Evaluation, and Objectivation. Pain Res. Treat. 2017; 2017:1-15.

Daniels NA, Link CL, Barry MJ, McKinlay JB. Association between past urinary tract infections and current symptoms suggestive of chronic prostatitis/chronic pelvic pain syndrome. J Natl Med Assoc. 2007; 99:509–516.

Arora, H.C, Shoskes D.A. Gut microbiome and chronic prostatitis/chronic pelvic pain syndrome. Ann. Transl. Med. 2017; 5:30.

Brünahl C, Dybowski C, Albrecht R, Riegel B, Höink J, Fisch M, Löwe B. Mental disorders in patients with chronic pelvic pain syndrome (CPPS). J. Psychosom. Res. 2017; 98:19–26.

Fu W, Zho Z, Liu S, Li Q, Yao J, Li W, Yan J. The Effect of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) on Semen Parameters in Human Males: A Systematic Review and Meta-Analysis. PLoS ONE. 2014; 9:94-91.

Hrncic, D., Sutulovic, N, Grubac, Z, Rasic-Markovic A, Stanojlovic O. The central nervous system is not imunoprivileged: Inflammation and epileptogenesis. Vojnosanit. Pregl. 2018; 75(8):820–825.

M. Potts, J. Male Pelvic Pain: Beyond Urology and Chronic Prostatitis. Curr. Rheumatol. 2016; 12:27–39.

Dersh J, Polatin PB, Gatchel RJ. Chronic pain and psychopathology:research findings and theoretical considerations. Psychosom Med. 2002; 64:773–786.

Marques L, Robinaugh DJ, LeBlanc NJ, Hinton D. Cross-cultural variations in the prevalence and presentation of anxiety disorders. Expert Rev Neurother. 2011; 11:313–322.

Spielberger C.D, Gorsuch RL, Lushene RE. Manual for the state-trait anxiety inventory (STAI). Palo Alto, CA: Consulting Psychologists Press Inc. 1983.

Pontari MA, McNaughton-Collins M, O’leary MP, Calhoun EA, Jang T. A case-control study of risk factors in men with chronic pelvic pain syndrome. BJU Int. 2005; 96:559–565.

Clemens JQ, Meenan RT, O’Keeffe Rosetti MC, Kimes T, Calhoun EA. Prevalence of and risk factors for prostatitis: population based assessment using physician assigned diagnoses. J Urol. 2007; 178:1333–1337.

Collins MM, Meigs JB, Barry MJ, Walker Corkery E, Giovannucci E. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol. 2002; 167:1363–1366.

Berghuis JP, Heiman JR, Rothman I, Berger RE. Psychological and physical factors involved in chronic idiopathic prostatitis. J Psychosom Res. 1996; 41:313–325.

J.J.M.C.H de la Rosette JJ, Hubregtse MR, Karthaus HF, Debruyne FM. Results of a questionnaire among Dutch urologists and general practitioners concerning diagnostics and treatment of patients with prostatitis syndromes. Eur Urol. 1992; 22:14–18.

Chung SD, Lin HC. Association between chronic prostatitis/chronic pelvic pain syndrome and anxiety disorder: a population-based study. PLoS One. 2013; 15:8-9.

Kraeuter AK, Guest PC, Sarnyai Z. The Open Field Test for Measuring Locomotor Activity and Anxiety-Like Behavior. Methods Mol Biol. 2019; 1916:99-103.

Radhakrishnan, R., Nallu, R.S. Development and characterisation of a novel animal model of prostate inflammation-induced chronic pelvic pain. Inflammopharmacology. 2009; 17:23–28.

Zeng, F, Chen H, Yang J, Wang L, Cui Y, et al. Development and Validation of an Animal Model of Prostate Inflammation-Induced Chronic Pelvic Pain: Evaluating from Inflammation of the Prostate to Pain Behavioral. J Neurosci. 2017; 38:1583–1590.

Zhang K, Zeng, X, Chen, Y, Zhao R., Wang H., Wu J. Therapeutic effects of Qian-Yu decoction and its three extracts on carrageenan-induced chronic prostatitis/chronic pelvic pain syndrome in rats. BMC Comp. Altern. Med. 2017; 17:75.

Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol. 2003; 463:3-33.

Simon P, Dupuis R, Costentin J. Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions. Behavioural Brain Research. 1994; 61:59-64.

Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol. 2003; 70:83-244.

Öztekin, İ., Akdere, H., Can, N., Aktoz, T., Arda, E., Turan, F.N., 2015. Therapeutic Effects of Oligonol, Acupuncture, and Quantum Light Therapy in Chronic Nonbacterial Prostatitis. Evid Based Complement Alternat Med. 2015; 2015:1–8.

Steimer T. Animal models of anxiety disorders in rats and mice: some conceptual issues. Dialogues Clin Neurosci. 2011; 13:495-506.

Ramos A, Correia EC, Izidio GS, Bruske GR. Genetic selection of two new rat lines displaying different levels of anxiety-related behaviors. Behav Genet 2003; 33:657-668.

Luheshi GN, Bluthe RM, Rushforth D, et al.Vagotomy attenuates the behavioural but not the pyrogenic effects of interleukin-1 in rats. Auton Neurosci. 2000; 85:127–32.

Breser, M.L, Salazar, F.C, Rivero, V.E, Motrich, R.D. Immunological Mechanisms Underlying Chronic Pelvic Pain and Prostate Inflammation in Chronic Pelvic Pain Syndrome. Front. Immunol. 2017; 8:898.

Jakobsson J, Bjerke M, Sahebi S, Isgren A, Ekman CJ, Sellgren C, et al. Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. JPN. 2015; 40:250–258.

Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA psychiatry. 2015; 72:268–275.

Wohleb ES, Patterson JM, Sharma V, Quan N, Godbout JP, Sheridan JF. Knockdown of interleukin-1 receptor type-1 on endothelial cells attenuated stress-induced neuroinflammation and prevented anxiety-like behavior. J Neurosci. 2014; 34:2583–2591.

Bergink V, Megen HJ, Westenberg HG. Glutamate and anxiety. Eur Neuropsychopharmacol. 2004; 14:175-183.

Garakani A, Mathew SJ, Charney DS. Neurobiology of anxiety disorders and implications for treatment. Mt Sinai J Med. 2006; 73:941-949.

Vaquero-Lorenzo C et al. Positive association between SAT-1-1415T/C polymorphism and anxiety. Am J Med Genet B Neuropsychiatr Genet. 2008; 150B(4):515-519.

Zou JY, Crews FT. TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res. 2005; 1034:11–24.

Vezzani A, Viviani B. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacology. 2015; 96:70–82.

Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010; 67:446–457.

Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009; 71:171–186.

Durackova Z. Some current insights into oxidative stress. Physiol Res. 2010; 59:459-69.

Bouayed J, Rammal H, Soulimani R. Oxidative stress and anxiety: relationship and cellular pathways. Oxid Med Cell Longev. 2009; 2:63-67.

Rammal H, Bouayed J, Younos C, Soulimani R. Evidence that oxidative stress is linked to anxietyrelated behaviour in mice. Brain Behav Immun. 2008; 22:1156-1159.

Hovatta I, Juhila J, Donner J. Oxidative stress in anxiety and comorbid disorders. Neurosci Res. 2010; 68:261-275.

Salim S, Sarraj N, Tanej M, Saha K, Tejada MV. Moderate treadmill exercise prevents oxidative stressinduced anxietylike behavior in rats. Behav Brain Res. 2010; 208:545-552.

Vazquez B, Devinsky O. Epilepsy and anxiety. Epilepsy Behav. 2003; 4:20-25.

Published
2019/12/31
Issue
Vol. 70 No. 4 (2019): Medicinski podmladak
Section
Original Scientific Paper